Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2
Ado-Trastuzumab Emtansine
/ therapeutic use
Adult
Aged
Antibodies, Monoclonal, Humanized
/ therapeutic use
Biomarkers, Tumor
Breast Neoplasms
/ drug therapy
Humans
Maytansine
/ therapeutic use
Middle Aged
Neoadjuvant Therapy
/ methods
Paclitaxel
/ therapeutic use
Receptor, ErbB-2
/ therapeutic use
Trastuzumab
/ therapeutic use
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
05 11 2021
05 11 2021
Historique:
received:
25
03
2021
accepted:
10
09
2021
entrez:
6
11
2021
pubmed:
7
11
2021
medline:
28
12
2021
Statut:
epublish
Résumé
HER2-targeted therapy dramatically improves outcomes in early breast cancer. Here we report the results of two HER2-targeted combinations in the neoadjuvant I-SPY2 phase 2 adaptive platform trial for early breast cancer at high risk of recurrence: ado-trastuzumab emtansine plus pertuzumab (T-DM1/P) and paclitaxel, trastuzumab and pertuzumab (THP). Eligible women have >2.5 cm clinical stage II/III HER2
Identifiants
pubmed: 34741023
doi: 10.1038/s41467-021-26019-y
pii: 10.1038/s41467-021-26019-y
pmc: PMC8571284
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Biomarkers, Tumor
0
Maytansine
14083FR882
Receptor, ErbB-2
EC 2.7.10.1
pertuzumab
K16AIQ8CTM
Trastuzumab
P188ANX8CK
Paclitaxel
P88XT4IS4D
Ado-Trastuzumab Emtansine
SE2KH7T06F
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
6428Informations de copyright
© 2021. The Author(s).
Références
N Engl J Med. 2016 Jul 7;375(1):23-34
pubmed: 27406347
Clin Cancer Res. 2014 Jan 15;20(2):278-80
pubmed: 24240115
N Engl J Med. 2016 Aug 25;375(8):717-29
pubmed: 27557300
Ann Oncol. 2013 Sep;24(9):2278-84
pubmed: 23704196
N Engl J Med. 2017 Jul 13;377(2):122-131
pubmed: 28581356
Lancet Oncol. 2012 Jan;13(1):25-32
pubmed: 22153890
N Engl J Med. 2016 Jul 7;375(1):11-22
pubmed: 27406346
Breast Cancer Res Treat. 2019 Nov;178(2):389-399
pubmed: 31428908
Ann Pharmacother. 2014 Nov;48(11):1484-93
pubmed: 25082874
Lancet Oncol. 2018 Jan;19(1):115-126
pubmed: 29175149
Clin Cancer Res. 2009 Nov 15;15(22):7003-11
pubmed: 19887485
PLoS One. 2014 Feb 07;9(2):e88309
pubmed: 24516633
Oncotarget. 2016 Sep 27;7(39):64431-64446
pubmed: 26824988
Clin Pharmacol Ther. 2009 Jul;86(1):97-100
pubmed: 19440188
Biostatistics. 2007 Jan;8(1):118-27
pubmed: 16632515
JCO Precis Oncol. 2018 Aug 16;2:
pubmed: 32914002
J Clin Oncol. 2009 Mar 10;27(8):1160-7
pubmed: 19204204
J Clin Oncol. 2007 Oct 1;25(28):4414-22
pubmed: 17785706
Ann Oncol. 2014 Jun;25(6):1116-21
pubmed: 24685829
N Engl J Med. 2015 Feb 19;372(8):724-34
pubmed: 25693012
J Clin Oncol. 2016 Feb 20;34(6):542-9
pubmed: 26527775
N Engl J Med. 2020 Feb 13;382(7):597-609
pubmed: 31825569
Lancet. 2014 Jul 12;384(9938):164-72
pubmed: 24529560